Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: A cohort study

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Dominiak Felden, Geraldine ^a   Gobbo, Corrado ^b   Simondon, François ^a,c  

^a SANOFI PASTEUR   (France)

^b Sanofi Pasteur MSD   (Belgium)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; BELGIUM; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; REIMBURSEMENT; RETROSPECTIVE STUDY; VACCINATION; YOUNG ADULT; CONDYLOMATA ACUMINATA; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

ADOLESCENT; ADULT; BELGIUM; COHORT STUDIES; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 84940093546     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132404     Document Type: Article

References (36)

1. Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ. 2007; 85(9):719-26. Epub 2007/11/21. PMID: 18026629; PubMed Central PMCID: PMCPmc2636411.
2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27. Epub 2003/02/07. doi: 10.1056/NEJMoa021641 PMID: 12571259.
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-9. Epub 1999/08/19. doi: 10.1002/(sici)1096-9896(199909)189:1〈12::aid-path431〉3.0.co;2-f PMID: 10451482.
4. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009; 199(6):805-14. Epub 2009/02/10. doi: 10.1086/597071 PMID: 19199546.
5. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006; 24 Suppl 3:S3/35-41. Epub 2006/09/05. doi: 10.1016/j.vaccine.2006.06.015 PMID: 16950016.
6. von Krogh G. Management of anogenital warts (condylomata acuminata). European journal of dermatology: EJD. 2001; 11(6):598-603; quiz 4. Epub 2001/11/10. PMID: 11701422.
7. Beutner KR, Wiley DJ, Douglas JM, Tyring SK, Fife K, Trofatter K, et al. Genital warts and their treatment. Clin Infect Dis. 1999; 28 Suppl 1:S37-56. Epub 1999/02/24. doi: 10.1086/514722 PMID: 10028109.
8. Dinh TH, Sternberg M, Dunne EF, Markowitz LE. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. Sex Transm Dis. 2008; 35(4):357-60. Epub 2008/03/25. doi: 10.1097/OLQ.0b013e3181632d61 PMID: 18360316.
9. Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis. 2007; 196(10):1447-54. Epub 2007/11/17. doi: 10.1086/522863 PMID: 18008222.
10. Desai S, Wetten S, Woodhall SC, Peters L, Hughes G, Soldan K. Genital warts and cost of care in England. Sexually transmitted infections. 2011; 87(6):464-8. Epub 2011/08/05. doi: 10.1136/sti.2010.048421 PMID: 21813567; PubMed Central PMCID: PMCPmc3253068.
11. Hillemanns P, Breugelmans JG, Gieseking F, Benard S, Lamure E, Littlewood KJ, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis. 2008; 8:76. Epub 2008/06/04. doi: 10.1186/1471-2334-8-76 PMID: 18518976; PubMed Central PMCID: PMCPmc2438362.
12. Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E. Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis. 2010; 10:360. Epub 2010/12/25. doi: 10.1186/1471-2334-10-360 PMID: 21182757; PubMed Central PMCID: PMCPmc3022833.
13. Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect. 2009; 85(2):111-5. Epub 2008/11/05. doi: 10.1136/sti.2008.030999 PMID: 18981170.
14. Dominiak-Felden G, Cohet C, Atrux-Tallau S, Gilet H, Tristram A, Fiander A. Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK. BMC public health. 2013; 13:1065. Epub 2013/11/13. doi: 10.1186/1471-2458-13-1065 PMID: 24215264; PubMed Central PMCID: PMCPmc4225724.
15. Lawrence S, Walzman M, Sheppard S, Natin D. The psychological impact caused by genital warts: has the Department of Health's choice of vaccination missed the opportunity to prevent such morbidity? Int J STD AIDS. 2009; 20(10):696-700. Epub 2009/10/10. doi: 10.1258/ijsa.2009.009120 PMID: 19815914.
16. Oriel JD. Natural history of genital warts. 1971. Sexually transmitted infections. 2000; 76 Suppl 1:S21. Epub 2000/07/27. PMID: 10911854.
17. Annemans L, Remy V, Lamure E, Spaepen E, Lamotte M, Muchada JP, et al. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. Journal of medical economics. 2008; 11(1):135-50. Epub 2008/01/01. doi: 10.3111/13696990801961611 PMID: 19450115.
18. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 341: c3493. Epub 2010/07/22. doi: 10.1136/bmj.c3493 PMID: 20647284; PubMed Central PMCID: PMCPMC2907480.
19. Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013; 31(48):5634-42. Epub 2013/07/17. doi: 10.1016/j.vaccine.2013.07.006 PMID: 23856332.
20. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013; 40(2):130-5. Epub 2013/01/18. doi: 10.1097/OLQ.0b013e31827bd66b PMID: 23324976.
21. Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst. 2013; 105(7):469-74. Epub 2013/03/15. doi: 10.1093/jnci/djt032 PMID: 23486550; PubMed Central PMCID: PMCPmc3614506.
22. Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis. 2013; 40(1):28-31. Epub 2012/12/20. doi: 10.1097/OLQ.0b013e3182756efd PMID: 23250300.
23. Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J. 2011; 124(1339):51-8. Epub 2011/09/29. PMID: 21952330.
24. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sexually transmitted infections. 2011; 87(7):544-7. Epub 2011/10/06. doi: 10.1136/sextrans-2011-050234 PMID: 21970896.
25. Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther. 2015; 32(1):10-30. Epub 2015/01/27. doi: 10.1007/s12325-015-0178-4 PMID: 25620536; PubMed Central PMCID: PMCPMC4311067.
26. Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK. Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J Infect Dis. 2012; 205(10):1544-53. doi: 10.1093/infdis/jis228 PMID: 22427679.
27. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013; 346:f2032. Epub 2013/04/20. doi: 10.1136/bmj.f2032 PMID: 23599298.
28. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009; 85(7):499-502. Epub 2009/10/20. doi: 10.1136/sti.2009.037788 PMID: 19837728.
29. Leval A, Herweijer E, Arnheim-Dahlstrom L, Walum H, Frans E, Sparen P, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012; 206(6):860-6. Epub 2012/07/21. doi: 10.1093/infdis/jis405 PMID: 22815381.
30. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health. 2013; 103(8):1428-35. Epub 2013/06/15. doi: 10.2105/ajph.2012.301182 PMID: 23763409.
31. Liu B, Donovan B, Brotherton JM, Saville M, Kaldor JM. Genital warts and chlamydia in Australian women: comparison of national population-based surveys in 2001 and 2011. Sex Transm Infect. 2014; 90(7):532-7. Epub 2014/02/27. doi: 10.1136/sextrans-2013-051307 PMID: 24570485.
32. Moreau N, de Smet P, I. G. Secondary school children's health: resuls from HBSC survey 2010 in the Federation of Wallonia-Brussels [La santé des élèves de l'enseignement secondaire: résultats de l'enquête HBSC 2010 en Fédération Wallonie-Bruxelles]. Brussels: 2013.
33. European Medicines Agency. Gardasil summary of product characteristics 2012 [updated 18 January 2012; cited 2012 23 January 2011]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human-med-000805.jsp&mid=WC0b01ac058001d124.
34. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19):1928-43. Epub 2007/05/15. doi: 10.1056/NEJMoa061760 PMID: 17494926.
35. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102(5):325-39. Epub 2010/02/09. doi: 10.1093/jnci/djp534 PMID: 20139221.
36. Verbrugge R, Moreels S, Crucitti T, van Beckhoven D, Sasse A, van Casteren V, et al. Sexually transmitted infections in the general population, data from 2013 for Belgium and its three regions [Infections sexuellement transmissibles dans la population générale, données de 2013 pour la Belgique et les 3 régions]. Brussels: 2014.